Islet cell replacement therapy - Sernova

Drug Profile

Islet cell replacement therapy - Sernova

Alternative Names: Cell Pouch™ - donor islet cells

Latest Information Update: 20 Jul 2016

Price : $50

At a glance

  • Originator Sernova Corp
  • Developer Sernova Corp; University of Alberta
  • Class Cell therapies
  • Mechanism of Action Pancreatic beta cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Haemophilia A; Type 1 diabetes mellitus

Highest Development Phases

  • Phase I/II Type 1 diabetes mellitus

Most Recent Events

  • 12 Jul 2016 Sernova plans a clinical trial for Type-1 diabetes mellitus (In hypoglycaemia unaware patients) in USA
  • 06 Jul 2016 Sernova terminates a phase I/II clinical trial in Type-1 diabetes mellitus in Canada (SC) (NCT01652911)
  • 10 Sep 2015 Sernova in-licenses proprietary stem cell derived technologies from the University Health Network (UHN) of Toronto for insulin-dependent diabetes
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top